Rocket Pharmaceuticals (RCKT) Insider & Congress Trades

Smart money at a glance

Filings to Oct 31, 2026

Net selling: insiders sold $432K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$432K netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 0 added, 1 cutMore cutting
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about RCKT filings

Are insiders buying or selling Rocket Pharmaceuticals Inc (RCKT) stock?

Net selling: insiders sold $432K and bought $0 of RCKT stock on the open market in the 90 days to Oct 31, 2026, according to SEC Form 4 filings. The largest was Wilson, Martin (General Counsel), who sold $270K. The latest filing was on Sep 16, 2026.

Which members of Congress have traded RCKT recently?

None. No member of Congress disclosed a RCKT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this RCKT smart-money data?

This summary uses filings available on Oct 31, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on RCKT

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $266K
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about RCKT filings

Are insiders buying or selling Rocket Pharmaceuticals Inc (RCKT) stock?

Which members of Congress have traded RCKT recently?

None. No member of Congress disclosed a RCKT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this RCKT smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$18.6MSells/Trims$9.8M

Buys/Adds (2)

AQ
AQR
Q1 2026 13F
$8.5M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
SS
State Street
Q1 2026 13F
$10.1M
added

Sells/Trims (1)

SS
State Street
Q2 2026 13F
$9.8M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 6, 2026

Earnings came in $0.43 a share below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 6, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.15-$0.43 miss

$0.28 expected

Revenue

$0.00

SEC filing

Next report

Estimated report: Nov 5, 2026, in 5 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 6, 2026	-$0.15est. $0.28	-$0.43miss	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported May 7, 2026	-$0.42est. -$0.45	+6.67%beat	$0.00SEC filing	No year-ago quarter
Dec 31, 2025Reported Feb 26, 2026	-$0.38est. -$0.42	+9.52%beat	$0.00Alpha Vantage	-100.0%from $9.2M
Sep 30, 2025Reported Nov 6, 2025	-$0.45est. -$0.52	+13.46%beat	$0.00SEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 7, 2025	-$0.59est. -$0.57	-3.51%miss	$0.00SEC filing	No year-ago quarter
Mar 31, 2025Reported May 8, 2025	-$0.56est. -$0.58	+3.45%beat	$0.00SEC filing	No year-ago quarter
Dec 31, 2024Reported Feb 27, 2025	-$0.62est. -$0.72	+13.64%beat	$9.2MAlpha Vantage	-10.9%from $10.3M
Sep 30, 2024Reported Nov 7, 2024	-$0.71est. -$0.75	+5.33%beat	$0.00SEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $2.50
52-wk high: $5.45
High: $2.57
52-wk low: $2.17
Low: $2.37
Prev close: $2.54
Mkt cap: $267.9M
ROE: -4.8%
Beta: 0.50
P/B: 0.8x
Profit margin: +0.0%
Op margin: +0.0%

Sep 2025 to Jun 2026

What it sold, what it cost, what was left.

RevenueProfit

Sep 2025Dec 2025Mar 2026Jun 2026

Income statement, 4 periods, all values in US dollars
USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
Cost of what it soldCost of revenue	—	—	$2.1M	—
Gross profit	—	—	-$2.1M	—
What it spent
Research and development	$34.1M	$29.3M	$31.5M	$29.5M
Sales and adminSelling, general and administrative	$18.4M	$14.7M	$17.1M	$17.4M
Other operating costsOperating costs not itemised in the filing's summary	—	—	-$2.1M	—
Total operating expenses	$52.2M	$44.0M	$46.4M	$46.9M
What was left
Operating profitOperating income	-$52.2M	-$44.0M	-$48.5M	-$46.9M
Interest on debtInterest expense	$473.0K	$3.3M	$473.0K	$473.0K
Profit before tax	-$50.3M	-$42.5M	-$47.6M	$131.8M
TaxIncome tax expense	—	—	—	$8.6M
Net profitNet income	-$50.3M	-$42.5M	-$47.6M	$123.2M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$46.6M	-$37.0M	-$45.0M	$134.4M

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

35 / 100

RSI 14

49balanced

20D volatility

75%annualized

52-week range

$2.44

$2.17$5.45

20D support

$2.17recent floor

20D resistance

$2.78recent ceiling

Returns

5D +6.6%20D -4.7%60D -31.1%

Price vs moving averages

SMA20 +1.6%SMA50 -17.7%SMA200 -29.3%

Volume pace

1.12xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Jun 30, 2026Aug 6, 2026

-$0.15est. $0.28

-$0.43

$0.00SEC filing

No year-ago quarter

Mar 31, 2026May 7, 2026

-$0.42est. -$0.45

+6.67%

$0.00SEC filing

No year-ago quarter

Dec 31, 2025Feb 26, 2026

-$0.38est. -$0.42

+9.52%

$0.00Alpha Vantage

-100.0%from $9.2M

Sep 30, 2025Nov 6, 2025

-$0.45est. -$0.52

+13.46%

$0.00SEC filing

No year-ago quarter

Jun 30, 2025Aug 7, 2025

-$0.59est. -$0.57

-3.51%

$0.00SEC filing

No year-ago quarter

Mar 31, 2025May 8, 2025

-$0.56est. -$0.58

+3.45%

$0.00SEC filing

No year-ago quarter

Dec 31, 2024Feb 27, 2025

-$0.62est. -$0.72

+13.64%

$9.2MAlpha Vantage

-10.9%from $10.3M

Sep 30, 2024Nov 7, 2024

-$0.71est. -$0.75

+5.33%

$0.00SEC filing

No year-ago quarter

Income statement, 4 periods, all values in US dollars
USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
Cost of what it soldCost of revenue	—	—	$2.1M	—
Gross profit	—	—	-$2.1M	—
What it spent
Research and development	$34.1M	$29.3M	$31.5M	$29.5M
Sales and adminSelling, general and administrative	$18.4M	$14.7M	$17.1M	$17.4M
Other operating costsOperating costs not itemised in the filing's summary	—	—	-$2.1M	—
Total operating expenses	$52.2M	$44.0M	$46.4M	$46.9M
What was left
Operating profitOperating income	-$52.2M	-$44.0M	-$48.5M	-$46.9M
Interest on debtInterest expense	$473.0K	$3.3M	$473.0K	$473.0K
Profit before tax	-$50.3M	-$42.5M	-$47.6M	$131.8M
TaxIncome tax expense	—	—	—	$8.6M
Net profitNet income	-$50.3M	-$42.5M	-$47.6M	$123.2M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$46.6M	-$37.0M	-$45.0M	$134.4M

USD

Sep 2025

Dec 2025

Mar 2026

Jun 2026

What came in

RevenueTotal revenue

Cost of what it soldCost of revenue

—

$2.1M

—

Gross profit

—

-$2.1M

—

What it spent

Research and development

$34.1M

$29.3M

$31.5M

$29.5M

Sales and adminSelling, general and administrative

$18.4M

$14.7M

$17.1M

$17.4M

Other operating costsOperating costs not itemised in the filing's summary

—

-$2.1M

—

Total operating expenses

$52.2M

$44.0M

$46.4M

$46.9M

What was left

Operating profitOperating income

-$52.2M

-$44.0M

-$48.5M

-$46.9M

Interest on debtInterest expense

$473.0K

$3.3M

$473.0K

Profit before tax

-$50.3M

-$42.5M

-$47.6M

$131.8M

TaxIncome tax expense

—

$8.6M

Net profitNet income

-$50.3M

-$42.5M

-$47.6M

$123.2M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$46.6M

-$37.0M

-$45.0M

$134.4M

Rocket Pharmaceuticals Inc

Smart money at a glance

What do analysts expect?

Questions about RCKT filings

Smart money on RCKT

Questions about RCKT filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.43 a share below what analysts expected.

Estimated report: Nov 5, 2026, in 5 days

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Rocket Pharmaceuticals Inc

Smart money at a glance

What do analysts expect?

Questions about RCKT filings

Smart money on RCKT

Questions about RCKT filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.43 a share below what analysts expected.

Estimated report: Nov 5, 2026, in 5 days

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Rocket Pharmaceuticals Inc

Overview

Questions about RCKT filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Rocket Pharmaceuticals Inc

Overview

Questions about RCKT filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.